Polymorphisms in vascular endothelial growth factor receptor 2 are associated 
with better response rates to ranibizumab treatment in age-related macular 
degeneration

Hermann, Manuel M.; van Asten, Freekje; Muether, Philipp S.; Smailhodzic, Dzenita; Lichtner, Peter; Hoyng, Carel B.; Kirchhof, Bernd; Grefkes, Christian; den Hollander, Anneke I.; Fauser, Sascha

doi:10.1016/j.ophtha.2013.10.047

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration

MPS-Authors

/persons/resource/persons147178

Grefkes, Christian
Neuromodulation und Neurorehabilitation, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Hermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., et al. (2014). Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration. Ophthalmology, 121(4), 905-910. doi:10.1016/j.ophtha.2013.10.047.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-D836-D